Music to Reduce Use of Smoking in Patients With Schizophrenia

NCT ID: NCT03190161

Last Updated: 2019-08-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-03-09
• Study Completion Date: 2018-09-17

Brief Summary

The purpose of this study is to explore the impact of self-selected music listening which targets disrupting the reward process maintaining smoking and additionally attenuating the reward processing deficits associated with schizophrenia. Five participants with schizophrenia/schizoaffective disorder who smoke/nicotine will participate in an individual session of self-selected music listening for a half an hour.

Conditions

Schizophrenia; Nicotine Dependence; Smoking, Tobacco

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Schizophrenia Patients

Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder

Group Type: EXPERIMENTAL

Music session

Intervention Type: BEHAVIORAL

Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.

Interventions

Music session

Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level \<6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
• smoked at least 10 cigarettes per day for the past month
• score of 4 or more on the Fagerstrom Test for Nicotine Dependence73
• psychiatric stability (e.g., no psychiatric hospitalizations within the last year, no expectation for medication change during study participation, no active suicidal ideation, no symptoms that interfere with ability to participate in study activities)
• the capacity to participate in the informed consent process

Exclusion Criteria

• being medically unstable (e.g., medical condition that requires frequent medical appointments or hospitalizations and interferes with ability to participate in study activities)
• report active substance abuse or testing positive drug or alcohol use
• taking bupropion, varenicline, nicotine replacement products and/or involved in any other smoking cessation treatment
• participating in any treatment or activity that includes music as a focus
• having a seizure disorder, other neurological illnesses, or a family history of seizures

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

NYU Langone Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kathleen Tracy, MD

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

New York University School of Medicine

New York, New York, United States

Countries

United States

Other Identifiers

17-00001

Identifier Type: -

Identifier Source: org_study_id